Corpus ID: 4937890

Mechanism of action of antidepressants.

@article{Artigas2002MechanismOA,
  title={Mechanism of action of antidepressants.},
  author={Francesc Casa{\~n}as Artigas and David J. Nutt and Richard C. Shelton},
  journal={Psychopharmacology bulletin},
  year={2002},
  volume={36 Suppl 2},
  pages={
          123-32
        }
}
A wide range of effective drugs is available for the treatment of major depression. The discovery of these agents has not always been the result of rational drug design. Tricyclic antidepressants formed the mainstay of treatment until the 1990s, and selective serotonin reuptake inhibitors (SSRIs) have dominated treatment over the last decade. However, the poor tolerability associated with tricyclic antidepressants and concerns about the efficacy of SSRIs has led to the search for alternative… Expand
Enhanced selective serotonin re-uptake inhibitors as antidepressants: 2004 – 2006
TLDR
Despite mixed results from clinical trials with several NK1 antagonists, effective therapeutic agents for depression may still emerge from compounds with combined serotonin reuptake inhibitor/NK1 antagonist properties. Expand
Review on Antidepressant Medication
TLDR
Antidepressant drugs are the mainstay for the treatment of depression and are recommended as first line treatment options in moderate and severe depression or mild or sub threshold depression that has persisted despite other interventions. Expand
Selective Serotonin Reuptake Inhibitors Potentiate the Rapid Antidepressant-Like Effects of Serotonin4 Receptor Agonists in the Rat
TLDR
In acute conditions, the 5-HT4 agonist prucalopride was able to counteract the inhibitory effect of the selective serotonin reuptake inhibitors (SSRI) fluvoxamine and citalopram on 5- HT neuron impulse flow, in Dorsal Raphé Nucleus cells selected for their high basal discharge. Expand
Antiparkinsonian Treatment for Depression in Parkinson's Disease: Are Selective Serotonin Reuptake Inhibitors Recommended?
Depression is a frequent comorbid syndrome in Parkinson's disease. It is a difficult symptom to manage, as patients continuously receive antiparkinsonian medication and may also have to be treatedExpand
A comparative study on efficacy of amitriptyline and escitalopram in the treatment of depression
TLDR
This study suggests that escitalopram is effective in the treatment of depression and its efficacy appears to be comparable to amitriptyline at the end of four weeks. Expand
Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature
TLDR
Based on pooled data from short-term randomized trials and from longer-term studies, vortioxetine appears to be well tolerated and to have a low incidence of adverse effects on sexual functioning, and there is no evidence as yet that vortioxidant is more clinically effective than other types of antidepressants. Expand
Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT2A, 5-HT2C, and the serotonin transporter.
TLDR
Phthalazinone-based compounds that potently bind to 5-HT2A, 5- HT2C, and the serotonin transporter are developed that presented promising anti-depressant effects comparable to fluoxetine and also synergistic effects with fluoxettine in forced swimming test, which implicates these compounds can be developed to help the treatment of major depressive disorder. Expand
Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology
  • P. Nathan
  • Chemistry, Medicine
  • Journal of psychopharmacology
  • 2001
TLDR
While reuptake inhibition may more than likely be responsible for most of the antidepressant effect, other mechanisms may also contribute alone or in combination to exert the overall antidepressant action. Expand
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
TLDR
Three main groups of diseases are considered, based on the evidence of monoamine involvement (schizophrenia, depression, obesity), the identification of monoamines in the diseases processes and the prospect of the involvement of monoaminergic mechanisms (epilepsy, Alzheimer's disease, stroke). Expand
Serotonin4 (5-HT4) Receptor Agonists Are Putative Antidepressants with a Rapid Onset of Action
TLDR
It is shown that serotonin(4) (5-HT(4)) agonists reduce immobility in the forced swimming test, displaying an antidepressant potential and pointing out 5-HT (4) receptor agonists as a putative class of antidepressants with a rapid onset of action. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Mechanism of action of antidepressant medications.
  • J. Feighner
  • Medicine, Psychology
  • The Journal of clinical psychiatry
  • 1999
TLDR
The new antidepressants, including the single-receptor selective serotonin reuptake inhibitors (SSRIs) and multiple-re receptor antidepressants venlafaxine, mirtazapine, bupropion, trazodone, and nefazodone are discussed. Expand
Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine.
  • S. Kasper
  • Psychology, Medicine
  • Journal of clinical psychopharmacology
  • 1997
TLDR
Efficacy findings from the limited number of comparative clinical trials conducted in this patient population were reviewed, and the contention that tricyclic antidepressants offer superior efficacy to the SSRIs and the reversible monoamine oxidase inhibitors in the treatment of severe depression is supported. Expand
SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression
TLDR
Mirtazapine has been termed a noradrenergic and specific serotonergic antidepressant (NaSSA) and Reboxetine is the first selective Noradrenaline reuptake inhibitor (NaRI) to be introduced since the tricyclics, and lacks immediateSerotonergic effects. Expand
Rapid onset of action of venlafaxine
  • S. Montgomery
  • Psychology, Medicine
  • International clinical psychopharmacology
  • 1995
It is important to evaluate a new antidepressant in terms of its efficacy in relation to that of reference agents such as the tricyclics and monoamine oxidase inhibitors. Newer antidepressants haveExpand
Brain noradrenaline and the mechanisms of action of antidepressant drugs
  • T. Svensson
  • Psychology, Medicine
  • Acta psychiatrica Scandinavica. Supplementum
  • 2000
TLDR
From this review emerges the notion that facilitation of brain noradrenergic neurotransmission may represent a more fundamental means to achieve maximal response in major depression than hitherto understood. Expand
Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists
TLDR
The treatment of patients with major depression using an SSRI and pindolol, a 5-HT1A/ beta-adrenoceptor antagonist, markedly reduced the latency of the antidepressant response in previously untreated patients and induced a rapid improvement in treatment-resistant patients. Expand
Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants.
TLDR
The results suggest that the neurobiological mechanisms underlying the antidepressant responses to different drugs involve alterations in the functioning of different neurotransmitter systems and reinforce the importance of changes in both the serotonin and catecholamine systems for successful antidepressant responses. Expand
Noradrenergic approaches to antidepressant therapy.
TLDR
Clinicians now have a range of antidepressants with variable neurotransmitter effects, different side effect profiles, and some interesting differences in functional utility in their armamentarium for treating depression, renewed interest in the role of neurotransmitters other than serotonin in the treatment of depression. Expand
Drug-Drug Interactions Involving Antidepressants: Focus on Venlafaxine
  • L. Ereshefsky
  • Chemistry, Medicine
  • Journal of clinical psychopharmacology
  • 1996
TLDR
In vitro and in vivo data indicate that venlafaxine either does not significantly inhibit or weakly inhibits the activity of isoenzymes CYP2C9, CYD2D6, CYP1A2, or CYP3A3/4, which is a major role in the metabolism of many commonly used drugs. Expand
Overview of antidepressants currently used to treat anxiety disorders.
  • J. Feighner
  • Medicine, Psychology
  • The Journal of clinical psychiatry
  • 1999
TLDR
Newer antidepressants, such as mirtazapine, nefazodone, and venlafaxine XR, may provide some benefits across the broad spectrum of anxiety disorders with the safety and tolerability that are the hallmarks of third generation antidepressants. Expand
...
1
2
3
4
5
...